Substantial equivalence is the FDA standard used in a 510(k) premarket notification to show that a new medical device is as safe and effective as a legally marketed predicate device. It requires the same intended use and either identical technological characteristics or differences that raise no new safety or effectiveness questions.
What is substantial equivalence?
Substantial equivalence is the legal test at the center of the FDA 510(k) pathway. It sits early in the regulatory phase of the device lifecycle, once a design concept is defined, and a manufacturer is deciding how to reach the US market. The standard comes from section 513(i) of the Federal Food, Drug, and Cosmetic (FD&C) Act and the regulations at 21 CFR 807.92. A new device is compared against a predicate, meaning a device already legally marketed in the United States. If the FDA agrees the two are substantially equivalent, it issues a clearance letter and the new device enters the same regulatory class as the predicate.
The comparison rests on two pillars: intended use and technological characteristics. The same intended use is non-negotiable. Technological characteristics can differ, but only when the difference does not create new questions about whether the device is safe and effective.
Why substantial equivalence matters in medical device development
For most Class II devices, the 510(k) is the gateway to sale, and substantial equivalence is what that submission has to prove. A weak or poorly matched predicate can trigger repeated deficiency letters, add months to a timeline, or end in a not substantially equivalent (NSE) decision that pushes the device toward premarket approval. That shift changes the economics of a program: a PMA demands independent clinical evidence and far more time and cost than a comparison-based submission.
The stakes reach past the submission itself. The predicate a team picks shapes its testing plan, its risk file under ISO 14971, and the indications it can claim in labeling. Choosing convenience rather than fit is one of the more expensive mistakes a device company can make, because the consequences tend to surface late, during FDA review, when they are hardest to fix.
How substantial equivalence works
FDA evaluates substantial equivalence through a structured decision process, often drawn as a flowchart in the agency’s 2014 guidance “The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications.” The core questions run in order:
- Is the predicate a legally marketed device? If not, the comparison cannot proceed.
- Does the new device have the same intended use? A different intended use ends the review with an NSE finding.
- Does it have the same technological characteristics? If yes, and performance is supported, the device is substantially equivalent.
- If the characteristics differ, do those differences raise new questions of safety or effectiveness?
- Do accepted methods exist to evaluate the differences, and do the data show the device is as safe and effective as the predicate?
Technological characteristics, defined in section 513(i)(1)(B), cover materials, design, energy source, and other features. Bridging a difference usually means performance data: bench and engineering testing, electromagnetic compatibility under the IEC 60601 series, biocompatibility per ISO 10993, software documentation aligned to IEC 62304, and sometimes clinical data. In December 2024, the FDA finalized guidance on Predetermined Change Control Plans (PCCPs), so a team citing a predicate that holds a PCCP compares against the predicate as originally cleared, not its later modified state.
Common challenges and best practices
The recurring failure point is predicate selection. Teams reach for a familiar or recently cleared device without checking whether its intended use truly matches, or whether it carries an unmitigated safety issue or a design-related recall. FDA’s September 2023 draft guidance on predicate best practices, still non-binding, points toward predicates cleared using well-established methods that meet or exceed current safety and performance expectations.
A few habits separate smooth submissions from stalled ones:
- Confirm the candidate predicate is still legally marketed and was not removed from the market for safety reasons.
- Write the intended-use statement to match the predicate precisely, and resist expanding indications beyond what the predicate supports.
- Build a side-by-side comparison table covering intended use, materials, design, and performance early, not at the end.
- Use a pre-submission meeting to test a predicate strategy with the FDA before committing to it.
Strong teams treat predicate analysis as a design-phase activity rather than paperwork assembled after the device is frozen.
How SJML helps with substantial equivalence
SJML’s Compliance-as-a-Service team supports medical device companies building substantial equivalence arguments for FDA 510(k) submissions. Work spans regulatory strategy and device classification, predicate research, and preparation of the technical file and design history file that backs a comparison. The team aligns intended-use statements, maps technological characteristics against candidate predicates, and helps plan the bench and biocompatibility testing that supports a claim. For firms pursuing parallel US and EU market access, SJML coordinates 510(k) work with CE marking and EU MDR routes.
Frequently asked questions
Substantial equivalence supports a 510(k) clearance, not an approval. FDA clears a device when it finds the device to be as safe and effective as a predicate. Approval is reserved for premarket approval (PMA), which applies to most Class III devices and requires independent evidence of safety and effectiveness rather than a comparison to an existing device.
A not substantially equivalent (NSE) determination places the device into Class III by default. The manufacturer can then pursue premarket approval, submit a De Novo request if the device is low to moderate risk, or select a different predicate and resubmit. FDA often flags De Novo eligibility in the NSE letter when it applies.
Yes. A submission may cite a primary predicate plus additional reference predicates, but every predicate must share the same intended use as the new device. Splitting one intended use across predicates with different uses will undermine the claim. FDA recommends naming the closest match as the primary predicate device.
No. FDA does not expect a new device to be identical to its predicate, and identical devices are rare. Differences in materials, design, or energy source are acceptable when the intended use stays the same, and performance data show the differences raise no new questions of safety or effectiveness.
Related terms
- Predicate Device
- 510(k) Premarket Notification
- De Novo Classification
- Premarket Approval (PMA)
- Intended Use
